Dr. Gianni Sorarù is an associate professor of Neurology at the Department of Neuroscience of the University of Padova. He has always been interested in the field of motor neuron diseases. At the MND Clinic of Padova, he is responsible for the multidisciplinary team. His research activity aims to integrate information derived from laboratory studies with clinical applications. In the context of national and international collaborations, he actively conducts clinical trials and participates in the creation of working groups, patient registries and biobanks.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.